Follow
Solid Tumor Cancer
Solid tumors are abnormal tissue without a liquid area. Most solid tumors are named for the location or type of cell in which they develop, such as breast cancer, prostate cancer, or skin cancer. While solid tumors can be benign, when malignant they are classified as solid tumor cancer.
NOV 30, 2023 | 12:00 PM
C.E. CREDITS
Pathology Perspective: Discover the critical need for genomic testing in cancer and explore the differences between traditional tissue biopsies and liquid genomic profiling. We'll dive i...
NOV 29, 2023 | 9:00 AM
Tumor genomic profiling can be complicated, especially for diseases that commonly have multiple different genomic biomarkers of interest, such as non-small cell lung cancer (NSCLC) and color...
NOV 16, 2023 | 10:00 AM
Across various stages of the clinical oncology workflow, from panel design to genomic testing and molecular tumor boards, the identification and validation of actionable genomic alterations...
NOV 01, 2023 | 8:00 AM
To bring your cutting-edge cell and gene therapies to the patients that need them as quickly as possible, you need access to the most knowledgeable scientists, innovative technologies, metho...
OCT 26, 2023 | 8:00 AM
In the era of advanced biotechnology, automation plays a crucial role in accelerating cancer research. Next-generation sequencing (NGS) technology has revolutionized cancer research, but lab...
OCT 12, 2023 | 8:00 AM
Patient-derived tumoroids, also known as cancer organoids, hold potential as cost-effective models for cancer immunotherapy research. Patient-derived tumor models, which mimic the tumor micr...
OCT 11, 2023 | 9:00 PM
Epigenetic modifications such as DNA methylation have long shown promise as potential biomarkers to diagnose and guide treatment of many human diseases, including multiple types of cancers....
SEP 28, 2023 | 7:00 AM
Webinars will be available for unlimited on-demand viewing after live event. Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the AS...
SEP 13, 2023 | 10:00 AM
Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsi...
September 13 at 10:00am CEST, 9:00am BST
Webinar airing too early or too late for you? This webinar will also be available: September 13 at 10:00am PDT, 1:00pm EDT https://www.labroots.com/ms/webinar/dpcr-liquidbiopsy-panel-2 and S...
September 13 at 9:30am IST, 12:00pm CST/SGT
Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsi...
JUN 15, 2023 | 7:00 AM
Liquid biopsies represent a transformation in the management of cancer as they have the potential to detect, characterize, and monitor cancers earlier than can be achieved with conventional...
MAY 24, 2023 | 8:00 AM
Recent advances in multi-omic approaches, including genomics, transcriptomics, and proteomics, enable a more comprehensive description of the tumor. This promises to accelerate the developme...
MAY 16, 2023 | 8:00 AM
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
MAY 02, 2023 | 8:00 AM
Abstract Learning Objectives Define a tertiary lymphoid structure in human cancer Describe the tumor microenvironment factors that influence the formation of tertiary lymphoid structures Ide...
MAR 30, 2023 | 12:05 PM
Dr. Ritterhouse's laboratory has implemented rapid and ultra rapid protocol for NSCLC genomic profiling, based on NGS. This has led to significant shortening of turn around time (TAT) an...
MAR 30, 2023 | 12:25 PM
Next-generation sequencing can detect multiple driver oncogenes simultaneously, enabling the analysis of limited amounts of biopsied tissue samples. . Druggable driver mutations cover more t...
MAR 30, 2023 | 12:25 PM
Next-generation sequencing can detect multiple driver oncogenes simultaneously, enabling the analysis of limited amounts of biopsied tissue samples. . Druggable driver mutations cover more t...
MAR 23, 2023 | 8:00 AM
Date: March 23, 2023 Time: 8:00am (PDT), 11:00am (EDT), 8:00pm (CEST) Across clinical oncology applications, from molecular testing to cancer research the ability to identify potentially act...
DEC 07, 2022 | 9:00 AM
Date: December 07, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) Join us for an exciting live panel webinar, as we celebrate the 60th anniversary of Gibco Cell Culture. The panelists...
OCT 26, 2022 | 8:00 AM
Date: October 26, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the pa...
OCT 05, 2022 | 9:00 AM
Learning Objectives 1. Identify 3 obstacles that inhibit the immune cell response to cancer. 2. List 3 aspects of T cells antitumor function that can be improved with costimulatory signals....
AUG 24, 2022 | 8:00 AM
Date: August 24, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Next Generation Sequencing (NGS) has evolved rapidly since the first sequencing platforms were commercially released ne...
MAR 30, 2023 | 12:25 PM
Next-generation sequencing can detect multiple driver oncogenes simultaneously, enabling the analysis of limited amounts of biopsied tissue samples. . Druggable driver mutations cover more t...